4.8 Review

Targeted drug delivery strategies for precision medicines

Journal

NATURE REVIEWS MATERIALS
Volume 6, Issue 4, Pages 351-370

Publisher

NATURE PORTFOLIO
DOI: 10.1038/s41578-020-00269-6

Keywords

-

Funding

  1. NIH Director's New Innovator Award [DP2-HD075698]
  2. NIH [R01-CA215719, R01-DK114321, R01-NS116353, R01-CA190642, UL1-TR002384, T32-CA062948, P30-CA008748]
  3. National Science Foundation [CAREER 1752506, PHY 1545832]
  4. American Cancer Society Research Scholar Grant [GC230452]
  5. Pershing Square Sohn Cancer Research Alliance
  6. Breast Cancer Foundation
  7. Stand Up to Cancer Foundation
  8. Geoffrey Beene Cancer Research Center
  9. Expect Miracles Foundation Financial Services Against Cancer
  10. Anna Fuller Fund
  11. Louis V. Gerstner Jr. Young Investigator's Fund
  12. Frank A. Howard Scholars Program
  13. Honorable Tina Brozman Foundation for Ovarian Cancer Research
  14. Cycle for Survival
  15. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center
  16. Commonwealth Foundation for Cancer Research
  17. Center for Experimental Therapeutics
  18. Imaging & Radiation Sciences Program
  19. Center for Molecular Imaging and Nanotechnology of Memorial Sloan Kettering Cancer

Ask authors/readers for more resources

Precision medicine offers personalized treatment strategies for individual patients, especially in the field of cancer therapy. While there have been some clinical successes, challenges such as drug toxicities and resistance still hinder the full potential of precision medicine. Advanced drug delivery materials and approaches provide opportunities to improve therapeutic outcomes and overcome pharmacological issues in cancer treatment.
Precision medicine identifies the optimal treatment strategy for an individual patient. Such personalized therapies can be greatly improved by targeted drug delivery approaches. This Review investigates the integration of targeted drugs, in particular, kinase inhibitors, with targeted drug delivery systems. Progress in the field of precision medicine has changed the landscape of cancer therapy. Precision medicine is propelled by technologies that enable molecular profiling, genomic analysis and optimized drug design to tailor treatments for individual patients. Although precision medicines have resulted in some clinical successes, the use of many potential therapeutics has been hindered by pharmacological issues, including toxicities and drug resistance. Drug delivery materials and approaches have now advanced to a point where they can enable the modulation of a drug's pharmacological parameters, without compromising the desired effect on molecular targets. Specifically, they can modulate a drug's pharmacokinetics, stability, absorption and exposure to tumours and healthy tissues, and facilitate the administration of synergistic drug combinations. This Review highlights recent progress in precision therapeutics and drug delivery, and identifies opportunities for strategies to improve the therapeutic index of cancer drugs and, consequently, clinical outcomes.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available